Wells Fargo analyst Tiago Fauth downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Overweight to Equal-Weight and lowers the price target from $35 to $2.
Wells Fargo Downgrades Aerovate Therapeutics to Equal-Weight, Lowers Price Target to $2
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.